X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
eFT508 (tomivosertib) is a potent and highly selective MNK inhibitor, small molecule drug candidate, which is being evaluated in combination with pembrolizumab for the treatment of non-small cell lung cancer.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
The net proceeds will focus on the development of eFT508 (tomivosertib), which is a small molecule inhibitor of MNK used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The net proceeds will be used to advance company's pipeline including, eFT508 (tomivosertib), an oral small molecule inhibitor of MNK1 and MNK2 and currently in Phase II for Head And Neck Cancer.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
The collaboration aims to evaluate eFT508 (tomivosertib), an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E, in patients with relapsed/refractory Acute Myeloid Leukemia.
Lead Product(s): Tomivosertib
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Northwestern University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2023
Details:
eFT505 (tomivosertib), a potent and highly selective inhibitor of the immunosuppressive kinases MNK-1 and 2, blocks the expression of checkpoint proteins PD-1, PD-L1, and LAG-3 as well as immunosuppressive cytokines IL-6 and IL-8.
Lead Product(s): Tomivosertib,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: eFT505
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Cohort two will assess the safety and efficacy of tomivosertib in combination with pembrolizumab at treatment initiation in the frontline setting. Both cohorts in the trial will have a control arm with placebo in combination with pembrolizumab.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
Transaction includes up to $175 m in trust at LWAC and a concurrent, fully committed $60 m PIPE offering. The funds will be used to Push eFFECTOR’s pipeline through multiple clinical milestones including expansion of tomivosertib and zotatifin into additional indications.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Locust Walk
Deal Size: $235.0 million Upfront Cash: Undisclosed
Deal Type: Merger May 27, 2021
Details:
In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with checkpoint inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment.
Lead Product(s): Tomivosertib,Anti PD1/PD-L1 therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
